Related Experiment Video

Updated: Jul 11, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

PKC isozymes in chronic cardiac disease: possible therapeutic targets?

Eric Churchill1, Grant Budas, Alice Vallentin

  • 1Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305-5174, USA.

Annual Review of Pharmacology and Toxicology
|October 9, 2007
PubMed

Insights

Targeting Protein Kinase C (PKC) offers a promising therapeutic strategy for cardiovascular diseases. This review explores isozyme-specific PKC regulators for treating heart conditions like atherosclerosis and hypertrophy.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality in the U.S.
  • Protein Kinase C (PKC) is implicated in heart disease pathologies.
  • Developing PKC-targeted drugs is challenging due to isozyme complexity and normal functions.

Purpose of the Study:

  • To review the therapeutic potential of targeting Protein Kinase C (PKC) in cardiovascular diseases.
  • To discuss the structure, function, and distribution of PKC isozymes in healthy and diseased hearts.
  • To examine the development of isozyme-selective PKC regulators for therapeutic applications.

Main Methods:

  • Review of existing literature on PKC structure, function, and role in cardiac pathologies.
  • Analysis of rationally designed, isozyme-selective PKC regulators.
  • Examination of pharmacological principles for targeting PKC signaling cascades.

Main Results:

  • PKC isozymes play critical roles in atherosclerosis, fibrosis, and cardiac hypertrophy.
  • Isozyme-specific targeting strategies are being developed to overcome challenges of PKC drug development.
  • Understanding PKC signaling is key to developing effective cardiovascular therapies.

Conclusions:

  • Targeting specific PKC isozymes presents a viable therapeutic avenue for cardiovascular diseases.
  • Isozyme-selective regulators offer improved specificity and reduced side effects.
  • Further research into PKC pharmacology can lead to novel treatments for heart conditions.

More Related Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK908:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...